JP2010259446A5 - - Google Patents

Download PDF

Info

Publication number
JP2010259446A5
JP2010259446A5 JP2010176512A JP2010176512A JP2010259446A5 JP 2010259446 A5 JP2010259446 A5 JP 2010259446A5 JP 2010176512 A JP2010176512 A JP 2010176512A JP 2010176512 A JP2010176512 A JP 2010176512A JP 2010259446 A5 JP2010259446 A5 JP 2010259446A5
Authority
JP
Japan
Prior art keywords
poxvirus
gene
recombinant poxvirus
recombinant
homologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010176512A
Other languages
English (en)
Japanese (ja)
Other versions
JP5777199B2 (ja
JP2010259446A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010259446A publication Critical patent/JP2010259446A/ja
Publication of JP2010259446A5 publication Critical patent/JP2010259446A5/ja
Application granted granted Critical
Publication of JP5777199B2 publication Critical patent/JP5777199B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2010176512A 2002-05-16 2010-08-05 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス Expired - Lifetime JP5777199B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200200752 2002-05-16
DKPA200200753 2002-05-16
DKPA200200753 2002-05-16
DKPA200200752 2002-05-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004506501A Division JP4693092B2 (ja) 2002-05-16 2003-05-14 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス

Publications (3)

Publication Number Publication Date
JP2010259446A JP2010259446A (ja) 2010-11-18
JP2010259446A5 true JP2010259446A5 (enExample) 2011-07-28
JP5777199B2 JP5777199B2 (ja) 2015-09-09

Family

ID=29551228

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2004506501A Expired - Lifetime JP4693092B2 (ja) 2002-05-16 2003-05-14 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス
JP2004506500A Expired - Lifetime JP4895505B2 (ja) 2002-05-16 2003-05-14 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域
JP2010176511A Pending JP2011004755A (ja) 2002-05-16 2010-08-05 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス
JP2010176512A Expired - Lifetime JP5777199B2 (ja) 2002-05-16 2010-08-05 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2004506501A Expired - Lifetime JP4693092B2 (ja) 2002-05-16 2003-05-14 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス
JP2004506500A Expired - Lifetime JP4895505B2 (ja) 2002-05-16 2003-05-14 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域
JP2010176511A Pending JP2011004755A (ja) 2002-05-16 2010-08-05 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス

Country Status (22)

Country Link
US (14) US7550147B2 (enExample)
EP (3) EP2253709B1 (enExample)
JP (4) JP4693092B2 (enExample)
KR (4) KR101005630B1 (enExample)
CN (6) CN101831411A (enExample)
AT (1) ATE315660T1 (enExample)
AU (4) AU2003242540A1 (enExample)
BR (2) BR0310051A (enExample)
CA (3) CA2812019A1 (enExample)
DE (1) DE60303218T2 (enExample)
DK (2) DK1407033T3 (enExample)
EA (3) EA007811B1 (enExample)
ES (1) ES2256776T3 (enExample)
IL (4) IL164177A0 (enExample)
MX (2) MXPA04010713A (enExample)
NO (3) NO334273B1 (enExample)
NZ (2) NZ536501A (enExample)
PL (2) PL218318B1 (enExample)
PT (1) PT1407033E (enExample)
SI (1) SI1407033T1 (enExample)
UA (1) UA82479C2 (enExample)
WO (2) WO2003097846A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4101327C1 (enExample) * 1991-01-18 1991-10-24 Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De
DE20122302U1 (de) * 2000-11-23 2005-02-24 Bavarian Nordic A/S Variante des Modifizierten Vaccinia-Ankara-Virus
JP4801880B2 (ja) * 2002-04-19 2011-10-26 バヴァリアン・ノルディック・アクティーゼルスカブ 新生仔予防接種用変異ワクシニアウイルスアンカラ
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EP2253709B1 (en) 2002-05-16 2018-04-11 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
UA85543C2 (ru) * 2002-09-05 2009-02-10 Бавариан Нордик А/С Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных
WO2005048957A2 (en) * 2003-02-20 2005-06-02 Therion Biologics Corporation Novel insertion sites in pox vectors
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
EP1807508A4 (en) * 2004-11-05 2008-03-12 Us Gov Health & Human Serv METHODS FOR PREPARING CELLS AND VIRUSES
NO347468B1 (no) * 2005-02-23 2023-11-13 Bavarian Nordic As Et modifisert Vacciniavirus Ankara (MVA) for anvendelse ved immunisering.
CA2651456A1 (en) * 2006-05-19 2007-11-29 Glycofi, Inc. Recombinant vectors
US9133478B2 (en) 2006-08-25 2015-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
EP2462930B1 (en) * 2006-11-09 2017-05-31 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using prime-boost approach
US8440202B2 (en) * 2006-11-09 2013-05-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
DK2118292T3 (da) * 2007-01-30 2011-10-24 Transgene Sa Papillomavirus E2-polypeptid der anvendes til vaccination
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
TW200844231A (en) * 2007-05-15 2008-11-16 Transgene Sa Vectors for multiple gene expression
AU2008260593A1 (en) * 2007-05-30 2008-12-11 Wyeth Raccoon poxvirus expressing genes of feline antigens
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
WO2009052328A1 (en) 2007-10-18 2009-04-23 Bn Immunotherapeutics Inc. Use of mva to treat prostate cancer
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
KR100894430B1 (ko) * 2008-11-11 2009-04-22 시스템디엔디(주) 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법
ES2618103T3 (es) * 2008-11-21 2017-06-20 Bavarian Nordic A/S Vector que comprende múltiples secuencias de nucleótidos homólogas
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
US20120135032A1 (en) 2009-10-08 2012-05-31 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
WO2011047324A1 (en) 2009-10-16 2011-04-21 The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
WO2011087839A1 (en) 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
AU2011230491A1 (en) * 2010-03-26 2012-10-18 Emergent Product Development Gaithersburg Inc. Ectodomains of influenza Matrix 2 protein, expression system, and uses thereof
NZ603620A (en) 2010-07-20 2015-01-30 Bavarian Nordic As Method for harvesting expression products
US20120328649A1 (en) * 2010-09-23 2012-12-27 Baxter Healthcare S.A. Recombinant Viral Vectors and Methods for Inducing an Immune Response to Yellow Fever Virus
EP2627774B1 (en) * 2010-10-15 2018-11-21 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) influenza vaccine
WO2012142529A2 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
KR20150021088A (ko) 2012-06-05 2015-02-27 디 오스트레일리언 내셔널 유니버시티 인터루킨-4 길항제를 이용한 백신접종
WO2014019718A1 (en) 2012-08-01 2014-02-06 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
EP2908851A1 (en) 2012-10-19 2015-08-26 Bavarian Nordic Inc. Methods and compositions for the treatment of cancer
RU2709771C2 (ru) * 2013-03-15 2019-12-19 Симентис Лимитед Иммунная модуляция
WO2014139587A1 (en) * 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR101623498B1 (ko) 2014-10-16 2016-05-24 대한민국 약독화 백시니아 바이러스주 kvac１０３
KR101645642B1 (ko) 2014-10-16 2016-08-11 대한민국 Kvac１０３ 유래의 재조합 백시니아 바이러스
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
BR112017026649A2 (pt) * 2015-06-15 2018-08-28 Bavarian Nordic As vacina de vírus de febre aftosa (fmdv) de vírus vaccinia ankara modificado (mva) recombinante
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
PL3402802T3 (pl) 2016-01-08 2023-06-05 Geovax, Inc. Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym
EP3407910B1 (en) 2016-01-29 2022-04-13 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
WO2017136419A1 (en) * 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
SG11201807051VA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
US10517944B2 (en) 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
CA3265584A1 (en) * 2016-08-19 2025-03-14 Sementis Ltd VIRUS VACCINES
WO2018064516A1 (en) * 2016-09-30 2018-04-05 Monsanto Technology Llc Method for selecting target sites for site-specific genome modification in plants
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
EP3638302B1 (en) * 2017-06-15 2024-03-13 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding hiv antigens, and methods of use thereof
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
JP2021523712A (ja) 2018-05-11 2021-09-09 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ（ｒｍｖａ）ワクチン及びその調製方法
JP2021535730A (ja) * 2018-05-11 2021-12-23 シティ・オブ・ホープCity of Hope 複数の部位メガロウイルス（ｃｍｖ）抗原の発現のためのｍｖａベクター及びその使用
CN116162654A (zh) 2018-09-15 2023-05-26 纪念斯隆凯特琳癌症中心 用于癌症免疫疗法的重组痘病毒
CN111979204B (zh) * 2019-05-24 2023-10-13 杭州功楚生物科技有限公司 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
EP3842065A1 (en) * 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
US20210299245A1 (en) * 2020-03-31 2021-09-30 Sementis Limited Attenuated poxvirus vector based vaccine for protection against covid-19
MX2023009008A (es) 2021-02-02 2023-10-05 Geovax Inc Constructos virales para usarse en potenciar el cebado de linfocitos t durante la vacunación.
KR20250048615A (ko) 2022-07-08 2025-04-09 바이로미슬, 인크. 종양용해 백시니아 바이러스 및 재조합 바이러스 및 그의 사용 방법
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPH0795956B2 (ja) * 1986-09-22 1995-10-18 京都大学長 ポックスウイルス由来発現制御領域
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5651972A (en) 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US6893845B1 (en) * 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
AU672359B2 (en) * 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
BE1004877A3 (fr) * 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
FR2679249B1 (fr) * 1991-07-15 1993-11-26 Centre Nal Recherc Scientifique Souches de levure avec integration stable de genes heterologues.
JPH06509235A (ja) 1991-07-26 1994-10-20 ヴァイロジェネティクス　コーポレイション 伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン
DE69133333T2 (de) * 1991-08-26 2004-07-29 Baxter Healthcare S.A. Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken
ATE181108T1 (de) * 1991-08-26 1999-06-15 Immuno Ag Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0753581A1 (en) * 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
DE19629828A1 (de) * 1996-07-24 1998-01-29 Bayer Ag Carbanilide
MY150893A (en) * 1996-09-24 2014-03-14 Bavarian Nordic As Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AUPP380598A0 (en) * 1998-05-29 1998-06-25 Commonwealth Scientific And Industrial Research Organisation Genetically manipulated entomopoxvirus
US6252871B1 (en) 1998-07-01 2001-06-26 Powerwave Technologies, Inc. Switchable combiner/splitter
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
US6682742B1 (en) * 1999-05-28 2004-01-27 Gsf Forschungszentrum Fur Unwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
NZ521270A (en) * 2000-03-14 2003-06-30 Bavarian Nordic As Altered strain of the Modified Vaccinia virus Ankara (MVA) for growth in a continuous vero cell line
CA2341356C (en) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
EP1326990B1 (en) * 2000-08-29 2007-09-19 Wyeth Holdings Corporation Packaging of positive-strand rna virus replicon particles
DE20122302U1 (de) * 2000-11-23 2005-02-24 Bavarian Nordic A/S Variante des Modifizierten Vaccinia-Ankara-Virus
EP2253709B1 (en) 2002-05-16 2018-04-11 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
DE60314541T2 (de) * 2002-11-25 2008-02-28 Bavarian Nordic A/S Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus

Similar Documents

Publication Publication Date Title
JP2010259446A5 (enExample)
JP2011004755A5 (enExample)
KR102135818B1 (ko) 강력한 ｔ-세포 및 항체 반응을 위한 ｐｒ13.5 프로모터
Cottingham et al. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA)
CN104894075B (zh) CRISPR/Cas9和Cre/lox系统编辑伪狂犬病毒基因组制备疫苗方法和应用
JP4693092B2 (ja) ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス
DK2558581T3 (en) POX VIRUS EXPRESSION SYSTEM
CA2777744C (en) Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
US20100233203A1 (en) Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against recombinant antigen in mva vaccines
CN105829537B (zh) 用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体
JP2013507935A5 (enExample)
Alharbi Poxviral promoters for improving the immunogenicity of MVA delivered vaccines
Zhu et al. The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes
CA2372709C (en) Vector for integration of heterologous sequences into poxviral genomes
CN105879060B (zh) 以成纤维激活蛋白α为靶点的肿瘤DNA疫苗及病毒载体疫苗
Alharbi et al. Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
CN103298936A (zh) 具有新型流感病毒来源的血凝素蛋白基因的重组痘苗病毒
Tscherne et al. Generating MVA-Vector Vaccine Candidates and Testing Them in Animal Models
Kan et al. Generation of an attenuated Tiantan vaccinia virus by deletion of the ribonucleotide reductase large subunit
CN102851293B (zh) 靶向抑制羊痘病毒ORF095基因的序列siRNA-165
JP5944210B2 (ja) 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子が組み込まれたｂ５ｒ遺伝子欠損組換えワクシニアウイルス
CN102796740B (zh) 靶向抑制羊痘病毒ORF095基因的序列siRNA-70
CN102417907B (zh) 靶向抑制羊痘病毒ORF095基因的siRNA序列
CN102827842B (zh) 靶向抑制羊痘病毒ORF095基因的序列siRNA-296
Spencer Matthew G. Cottingham, Rikke F. Andersen, Alexandra J. Spencer, Saroj Saurya, Julie Furze, Adrian VS Hill and Sarah C. Gilbert